FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
Pharmacy Best Practices
With the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.
CAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.
CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.
A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.
Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?
External, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.
New Yale University research offers stunning findings about drug formulary coverage and prescribing opioids.
Recent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.